LEO Pharma’s Atopic Dermatitis Med Tralokinumab Up for MHLW Panel Review on November 28

November 15, 2022
Japan’s key health ministry panel will discuss whether to back the approval of a host of medicines, including LEO Pharma’s antibody drug tralokinumab for the indication of atopic dermatitis, at its upcoming meeting on November 28. Tralokinumab is one of...read more